{"filing":{"accession_number":"0001636282-26-000113","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"syre-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm"},"events":[{"id":31818,"run_id":29217,"accession_number":"0001636282-26-000113","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23) in ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p\u003c0.0001) and clinical remission rates of 20%, meeting all key efficacy and safety objectives. This represents a material clinical development milestone and proof-of-concept for a key pipeline asset, advancing the company's combination strategy and strengthening its IBD program.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34815,"accession_number":"0001636282-26-000113","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23), demonstrating a statistically significant 10.0-point reduction in RHI score (p\u003c0.0001) and meeting all key efficacy and safety objectives. This is a material clinical development milestone for a clinical-stage biotech company, representing proof-of-concept for a key pipeline asset and advancing the company's combination strategy. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical readout is a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:03:52.327907+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34816,"accession_number":"0001636282-26-000113","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Spyre announced positive Phase 2 clinical trial data for SPY003 (anti-IL-23) in the SKYLINE trial for ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p\u003c0.0001) and clinical remission rates of 20%. This represents a material operational/clinical milestone for a clinical-stage biotech company—the achievement of proof-of-concept across all three IBD program components strengthens the company's development strategy and pipeline. While this is not a traditional earnings release (the company is pre-revenue), it is a significant clinical development milestone that would materially affect investor assessment of the registrant's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:03:52.327907+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34815,"accession_number":"0001636282-26-000113","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23), demonstrating a statistically significant 10.0-point reduction in RHI score (p\u003c0.0001) and meeting all key efficacy and safety objectives. This is a material clinical development milestone for a clinical-stage biotech company, representing proof-of-concept for a key pipeline asset and advancing the company's combination strategy. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical readout is a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:03:52.327907+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-09-08"},{"id":34816,"accession_number":"0001636282-26-000113","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Spyre announced positive Phase 2 clinical trial data for SPY003 (anti-IL-23) in the SKYLINE trial for ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p\u003c0.0001) and clinical remission rates of 20%. This represents a material operational/clinical milestone for a clinical-stage biotech company—the achievement of proof-of-concept across all three IBD program components strengthens the company's development strategy and pipeline. While this is not a traditional earnings release (the company is pre-revenue), it is a significant clinical development milestone that would materially affect investor assessment of the registrant's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:03:52.327907+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-09-08"}]}